Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #9811
Ace Report Cover Osteoarthritis

Rofecoxib and celecoxib demonstrate similar, significant 6-week efficacy vs placebo in OA treatment

Study Type:Therapy
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies

Curr Med Res Opin. 2006 Jan;22(1):199-210

Contributing Authors: AM Tershakovec DJ Chang C Birbara G Ruoff E Sheldon C Valenzuela A Rodgers RA Petruschke

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


808 patients, combined from two trials, with knee osteoarthritis were randomized to receive either celecoxib 200mg daily, rofecoxib 12.5mg daily, or placebo. Patients were assessed over a 6-week period of treatment on a Patient Global Assessment of Response to Therapy (PGART), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Physical Function subscales, and the i...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.